Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells

Area of Science:

• Endocrinology and Metabolism
• Drug Delivery Systems
• Cell Biology

Background:

• Diabetes mellitus is characterized by pancreatic beta-cell dysfunction and depletion.
• Current in vivo methods for monitoring beta-cell function exist, but targeted therapeutic delivery remains a challenge.
• Beta cells possess a unique ability to concentrate zinc, a property not fully exploited for therapeutic strategies.

Purpose of the Study:

• To investigate the potential of using beta cells' high zinc content for targeted delivery of therapeutic compounds.
• To determine if zinc-binding molecules can be preferentially trapped within beta cells for enhanced drug delivery.
• To develop a proof-of-concept for beta-cell-targeted drug delivery and bioactivity.

Main Methods:

• Utilized the zinc-concentrating ability of beta cells to trap zinc-binding molecules.
• Assessed the preferential accumulation of TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline) in zinc-rich beta cells and islets compared to exocrine pancreas.
• Synthesized and evaluated a hybrid compound by appending a zinc-chelating moiety to a beta-cell replication-inducing agent.

Main Results:

• Zinc-rich beta cells and islets demonstrated preferential accumulation of TSQ in a zinc-dependent manner.
• The synthesized hybrid compound also showed preferential accumulation within rodent and human islets, dependent on zinc levels.
• The hybrid compound exhibited increased selectivity of replication-promoting activity towards beta cells.

Conclusions:

• Intracellular accumulation of zinc-chelating compounds is significantly influenced by cellular zinc content.
• This study establishes a fundamental principle for enhancing drug accumulation in zinc-rich cells.
• A novel, zinc-based strategy for targeted beta-cell drug delivery and improved bioactivity in diabetes treatment has been demonstrated.